Patents by Inventor Philippe Picaut

Philippe Picaut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AMITRIPTYLINE AND AN ALKALINE AQUEOUS PHASE
    Publication number: 20240041766
    Abstract: The present invention relates to a topical pharmaceutical composition in the form of an oil-in-water emulsion comprising an oily phase based on amitriptyline in its basic form and an alkaline aqueous phase. The invention also relates to a method for treating neuropathic pain or erythromelalgia comprising the topical application to the patient of a pharmaceutical composition according to the invention.
    Type: Application
    Filed: March 15, 2022
    Publication date: February 8, 2024
    Applicant: AlgoTherapeutix
    Inventors: Frédéric Lallemand, Philippe PICAUT
  • Treatment of Upper Facial Lines
    Publication number: 20230346674
    Abstract: The present invention relates to a modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT/A is administered by way of a unit dose of Units to 41 Units of modified BoNT/A per site and wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines; and up to three sites at the external part of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 574 Units, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU
    Type: Application
    Filed: March 16, 2021
    Publication date: November 2, 2023
    Inventors: Nicolae GRIGORE, Katie RUFFLE, Philippe PICAUT
  • Treatment of Limb Spasticity
    Publication number: 20230248811
    Abstract: The present invention relates to a modified botulinum neurotoxin A (BoNT/A) for use in treating limb spasticity or paediatric limb spasticity, wherein the modified BoNT/A is administered by intramuscular injection to a plurality of affected muscles of a subject, wherein the modified BoNT/A is administered by way of a unit dose of 53 Units to 948 Units or 26.5 Units to 474 Units of modified BoNT/A at the plurality of affected muscles.
    Type: Application
    Filed: March 16, 2021
    Publication date: August 10, 2023
    Inventors: Nicolae GRIGORE, Katie RUFFLE, Philippe PICAUT
  • USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVE
    Publication number: 20220387594
    Abstract: The present invention relates to a method for the preservation of a pharmaceutical composition by adding amitriptyline and/or one of the pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 2, 2022
    Publication date: December 8, 2022
    Applicant: AlgoTherapeutix
    Inventors: Frédéric LALLEMAND, Philippe PICAUT
  • COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY
    Publication number: 20080058381
    Abstract: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
    Type: Application
    Filed: November 8, 2007
    Publication date: March 6, 2008
    Applicant: Aventis Pharma S.A.
    Inventors: Odile Piot-Grosjean, Philippe Picaut, Francois Petitet
  • Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
    Patent number: 7148258
    Abstract: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: December 12, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Odile Piot-Grosjean, Philippe Picaut, Francois Petitet
  • COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY
    Publication number: 20060258709
    Abstract: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
    Type: Application
    Filed: August 1, 2006
    Publication date: November 16, 2006
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Odile PIOT-GROSJEAN, Philippe PICAUT, Francois PETITET
  • Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
    Patent number: 7037944
    Abstract: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: May 2, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Odile Piot-Grosjean, Philippe Picaut, François Petitet
  • Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity
    Publication number: 20050032773
    Abstract: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
    Type: Application
    Filed: September 15, 2004
    Publication date: February 10, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Odile Piot-Grosjean, Philippe Picaut, Francois Petitet
  • Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
    Publication number: 20050032774
    Abstract: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
    Type: Application
    Filed: September 15, 2004
    Publication date: February 10, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Odile Piot-Grosjean, Philippe Picaut, Francois Petitet
  • Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
    Publication number: 20020091114
    Abstract: The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
    Type: Application
    Filed: October 3, 2001
    Publication date: July 11, 2002
    Inventors: Odile Piot-Grosjean, Philippe Picaut, Francois Petitet